

Irene Litvan,, Faan, Fana

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4064285/irene-litvan-faan-fana-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

379
papers

42,558
citations

90
h-index

203
g-index

407
ext. papers

49,874
ext. citations

6
avg, IF

6.82
L-index

#	Paper	IF	Citations
379	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. <i>Neurology</i> , 2005 , 65, 1863-72	6.5	3921
378	The FAB: a Frontal Assessment Battery at bedside. <i>Neurology</i> , 2000 , 55, 1621-6	6.5	2701
377	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
376	Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. <i>Neurology</i> , 1996 , 47, 1-9	6.5	2130
375	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
374	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
373	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014 , 46, 989-93	36.3	1261
372	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013 , 80, 496-503	6.5	1004
371	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
370	Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007 , 22, 2314-24	7	708
369	Association of an extended haplotype in the tau gene with progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 1999 , 8, 711-5	5.6	677
368	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
367	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , 2009 , 8, 1150-7	24.1	567
366	Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). <i>Neurology</i> , 1994 , 44, 2015-9	6.5	563
365	Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. <i>Lancet Neurology</i> , 2009 , 8, 1128-39	24.1	528
364	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
363	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. <i>Acta Neuropathologica</i> , 2016 , 131, 75-86	14.3	524

362	Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002 , 61, 935-46	3.1	462
361	Apathy is not depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998 , 10, 314-9	2.7	437
360	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S15-9	9.4	423
359	Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. <i>Neurology</i> , 1997 , 48, 119-25	6.5	391
358	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011 , 43, 699-705	36.3	386
357	Cognitive planning deficit in patients with cerebellar atrophy. <i>Neurology</i> , 1992 , 42, 1493-6	6.5	370
356	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. <i>Human Genetics</i> , 2009 , 124, 593-605	6.3	363
355	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001 , 56, 1702-6	6.5	358
354	Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). <i>Neurology</i> , 1996 , 46, 922-30	6.5	338
353	Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996 , 55, 97-105	3.1	311
352	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-82		305
351	Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). <i>Annals of Neurology</i> , 2008 , 63, 295-302	9.4	291
350	Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. <i>Archives of Neurology</i> , 2001 , 58, 259-64		291
349	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
348	Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. <i>Archives of Neurology</i> , 1998 , 55, 969-78		278
347	Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 60, 615-20	5.5	268
346	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248
345	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. <i>JAMA Neurology</i> , 2014 , 71, 543-52	17.2	239

344	Lrrk2 and Lewy body disease. <i>Annals of Neurology</i> , 2006 , 59, 388-93	9.4	237
343	Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 64, 184-9	5.5	229
342	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. <i>Annals of Neurology</i> , 2012 , 71, 370-84	9.4	214
341	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology, The</i> , 2017 , 16, 552-563	24.1	209
340	Neuropsychiatric aspects of progressive supranuclear palsy. <i>Neurology</i> , 1996 , 47, 1184-9	6.5	208
339	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014 , 29, 470-8	7	201
338	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 676-85	24.1	197
337	What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. <i>Archives of Neurology</i> , 1997 , 54, 937-44		194
336	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. <i>Neurology</i> , 1999 , 53, 1292-9	6.5	191
335	Slowed information processing in multiple sclerosis. <i>Archives of Neurology</i> , 1988 , 45, 281-5		188
334	Phosphorylated Synuclein in Parkinson's disease. <i>Science Translational Medicine</i> , 2012 , 4, 121ra20	17.5	182
333	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
332	Visualizing cortical activation during mental calculation with functional MRI. <i>NeuroImage</i> , 1996 , 3, 97-103	7.9	167
331	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 1215-20	5.5	163
330	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
329	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005 , 14, 3281-92	5.6	144
328	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. <i>Brain</i> , 2005 , 128, 570-83	11.2	144
327	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009 , 16, 297-309	6	143

326	Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. <i>Neurology</i> , 2001 , 57, 467-73	6.5	137
325	Multiple memory deficits in patients with multiple sclerosis. Exploring the working memory system. <i>Archives of Neurology</i> , 1988 , 45, 607-10		137
324	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. <i>NeuroImage</i> , 2004 , 21, 714-24	7.9	135
323	Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 620-3	5.5	134
322	Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. <i>Archives of Neurology</i> , 2006 , 63, 826-32		131
321	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017 , 32, 955-971	7	127
320	Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2000 , 54, 1029-32	6.5	127
319	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 2501-7	7	124
318	Progression of falls in postmortem-confirmed parkinsonian disorders. <i>Movement Disorders</i> , 1999 , 14, 947-50	7	122
317	Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene. <i>Neurology</i> , 1998 , 50, 270-3	6.5	120
316	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015 , 6, 7247	17.4	118
315	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. <i>Neurology</i> , 2009 , 73, 1469-77	6.5	114
314	Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. <i>Brain</i> , 1997 , 120 (Pt 1), 65-74	11.2	114
313	Update on epidemiological aspects of progressive supranuclear palsy. <i>Movement Disorders</i> , 2003 , 18 Suppl 6, S43-50	7	114
312	Importance of deficits in executive functions. <i>Lancet, The</i> , 1999 , 354, 1921-3	40	112
311	Neuropsychiatric features of corticobasal degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 65, 717-21	5.5	110
310	Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. <i>Brain</i> , 1997 , 120 (Pt 9), 1541-52	11.2	107
309	F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017 , 82, 622-634	9.4	106

308	Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. <i>Neurology</i> , 1999 , 53, 1910-21	6.5	106
307	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 31	7.3	104
306	Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 42-9	2.7	104
305	Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. <i>Archives of Neurology</i> , 1998 , 55, 1313-9		103
304	Frontal lobe function in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1990 , 47, 553-8		103
303	Environmental Exposures and Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2016 , 13,	4.6	102
302	α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. <i>Nature Communications</i> , 2020 , 11, 1875	17.4	102
301	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
300	A reappraisal of reliability and validity studies in stroke. <i>Stroke</i> , 1996 , 27, 2331-6	6.7	101
299	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. <i>Movement Disorders</i> , 2005 , 20, 982-8	7	100
298	"Applause sign" helps to discriminate PSP from FTD and PD. <i>Neurology</i> , 2005 , 64, 2132-3	6.5	100
297	Progressive supranuclear palsy: a survey of the disease course. <i>Neurology</i> , 1998 , 50, 1637-47	6.5	100
296	Measuring mild cognitive impairment in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 626-33	7	98
295	Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. <i>ACS Sensors</i> , 2019 , 4, 2196-2204	9.2	94
294	Pharmacological therapy in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1998 , 55, 1099-102		93
293	Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. <i>Neurology</i> , 2000 , 55, 888-91	6.5	92
292	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 1077-81	7	90
291	Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. <i>Neurology</i> , 2008 , 71, 28-34	6.5	90

290	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003 , 60, 917-22	6.5	90
289	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88
288	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 251-7	3.1	88
287	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. <i>Brain</i> , 2011 , 134, 3264-75	11.2	87
286	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017 , 12, e0175674	3.7	84
285	Behavioral abnormalities in progressive supranuclear palsy. <i>Psychiatry Research</i> , 2013 , 210, 1205-10	9.9	82
284	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. <i>Lancet Neurology</i> , 2019 , 18, 549-558	24.1	78
283	Genomewide association study for onset age in Parkinson disease. <i>BMC Medical Genetics</i> , 2009 , 10, 98	2.1	78
282	Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991 , 54, 25-9	5.5	78
281	Implicit learning in patients with Alzheimer's disease. <i>Pharmacopsychiatry</i> , 1990 , 23, 94-101	2	76
280	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017 , 32, 1056-1065	7	75
279	Characterizing swallowing abnormalities in progressive supranuclear palsy. <i>Neurology</i> , 1997 , 48, 1654-62	6.5	75
278	Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2001 , 56, 957-63	6.5	75
277	What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. <i>Neurology</i> , 1997 , 49, 62-9	6.5	73
276	The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. <i>BMC Medicine</i> , 2008 , 6, 32	11.4	72
275	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2015 , 36, 1605.e7-12	5.6	70
274	Reliability of the NINDS Myotatic Reflex Scale. <i>Neurology</i> , 1996 , 47, 969-72	6.5	69
273	Language disturbances in corticobasal degeneration. <i>Neurology</i> , 2000 , 54, 990-2	6.5	68

272	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
271	Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. <i>Journal of Neurochemistry</i> , 2000 , 75, 1681-4	6	66
270	Progressive supranuclear palsy: a clinicopathological study of 21 cases. <i>Acta Neuropathologica</i> , 1996 , 91, 427-31	14.3	64
269	β-synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016 , 79, 991-9	9.4	64
268	Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. <i>Archives of Clinical Neuropsychology</i> , 2013 , 28, 104-13	2.7	63
267	Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions. <i>Sensors</i> , 2017 , 17,	3.8	61
266	Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. <i>American Journal of Human Genetics</i> , 2007 , 80, 769-78	11	61
265	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , 2016 , 15, 546-8	24.1	61
264	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015 , 10, 50	19	60
263	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011 , 7, e60-e76	1.2	59
262	Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. <i>Neurology</i> , 2006 , 66, 949-50	6.5	59
261	Instrumental activities of daily living are impaired in Parkinson's disease patients with mild cognitive impairment. <i>Neuropsychology</i> , 2014 , 28, 229-37	3.8	58
260	Milestones in atypical and secondary Parkinsonisms. <i>Movement Disorders</i> , 2011 , 26, 1083-95	7	58
259	BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. <i>Neurology</i> , 2005 , 65, 1823-5	6.5	58
258	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56
257	Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. <i>European Journal of Neurology</i> , 2001 , 8, 707-10	6	55
256	Neuropsychological features of progressive supranuclear palsy. <i>Brain and Cognition</i> , 1995 , 28, 311-20	2.7	55
255	Copy number variation in familial Parkinson disease. <i>PLoS ONE</i> , 2011 , 6, e20988	3.7	53

254	Alzheimer's disease presenting as corticobasal syndrome. <i>Movement Disorders</i> , 2006 , 21, 2018-22	7	53
253	Measuring quality of life in PSP: the PSP-QoL. <i>Neurology</i> , 2006 , 67, 39-44	6.5	53
252	Selective deficits in cognition and memory in high-functioning parkinsonian patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990 , 53, 603-6	5.5	53
251	Cytokine expression and microglial activation in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 683-8	3.6	51
250	Memory impairment in patients with progressive supranuclear palsy. <i>Archives of Neurology</i> , 1989 , 46, 765-7		51
249	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. <i>BMC Neurology</i> , 2001 , 1, 3	3.1	50
248	Diagnosis and management of progressive supranuclear palsy. <i>Seminars in Neurology</i> , 2001 , 21, 41-8	3.2	50
247	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2020 , 139, 63-77	14.3	49
246	A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 423-6	3.6	48
245	Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. <i>Annals of Neurology</i> , 1994 , 36, 55-61	9.4	48
244	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. <i>Neurology</i> , 2016 , 87, 2016-2025	6.5	45
243	Parkinsonian syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013 , 19, 1189-212	3	45
242	Pupillary diameter assessment: need for a graded scale. <i>Neurology</i> , 2000 , 54, 530-1	6.5	45
241	Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 360-7	7	44
240	Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <i>Journal of Neural Transmission</i> , 1998 , 105, 217-27	4.3	44
239	Parkinson's disease mild cognitive impairment: application and validation of the criteria. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 131-7	5.3	42
238	Corticobasal degeneration. <i>Seminars in Neurology</i> , 2014 , 34, 160-73	3.2	41
237	White-matter changes correlate with cognitive functioning in Parkinson's disease. <i>Frontiers in Neurology</i> , 2013 , 4, 37	4.1	40

- 236 Parkinsonism and frontotemporal dementia: the clinical overlap. *Journal of Molecular Neuroscience*, **2011**, 45, 343-9 3.3 39
- 235 Freezing of gait in postmortem-confirmed atypical parkinsonism. *Movement Disorders*, **2002**, 17, 1041-5 7 39
- 234 Preserved cognitive processes in cerebellar degeneration. *Behavioural Brain Research*, **1996**, 79, 131-5 3.4 39
- 233 Annonacin in *Asimina triloba* fruit: implication for neurotoxicity. *NeuroToxicology*, **2012**, 33, 53-8 4.4 38
- 232 The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 329-36 3.1 38
- 231 Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. *Journal of Neural Transmission*, **1997**, 104, 845-65 4.3 37
- 230 Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. *Dementia and Geriatric Cognitive Disorders*, **2013**, 36, 67-75 2.6 36
- 229 Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. *Movement Disorders*, **2001**, 16, 1098-104 7 36
- 228 Physostigmine treatment of progressive supranuclear palsy. *Annals of Neurology*, **1989**, 26, 404-7 9.4 36
- 227 Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. *Movement Disorders*, **2016**, 31, 644-52 7 36
- 226 Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. *European Journal of Neurology*, **1998**, 5, 451-457 6 35
- 225 Abolishing the 1-year rule: How much evidence will be enough?. *Movement Disorders*, **2016**, 31, 1623-1627 35
- 224 Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). *Pharmacotherapy*, **2014**, 34, 1250-8 5.8 34
- 223 Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. *Movement Disorders*, **2018**, 33, 503-510 7 33
- 222 Progressive supranuclear palsy: progression and survival. *Journal of Neurology*, **2016**, 263, 380-389 5.5 33
- 221 The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. *Parkinsonism and Related Disorders*, **2014**, 20, 627-31 3.6 33
- 220 Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. *Neurology*, **2006**, 67, 2206-10 6.5 33
- 219 Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. *Neurology*, **2001**, 57, 138-40 6.5 33

218	Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 292-7	1	33
217	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. <i>PLoS ONE</i> , 2016 , 11, e0157218	3.7	33
216	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021 , 80, 210-219	3.1	32
215	Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. <i>Archives of Neurology</i> , 1990 , 47, 1346-50		31
214	Recent advances in atypical parkinsonian disorders. <i>Current Opinion in Neurology</i> , 1999 , 12, 441-6	7.1	31
213	Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 343-52	2.5	30
212	Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 535-9	3.6	29
211	Update on progressive supranuclear palsy. <i>Current Neurology and Neuroscience Reports</i> , 2004 , 4, 296-302	6.6	29
210	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2021 , 20, 182-192	24.1	29
209	Long-duration Parkinson's disease: role of lateralization of motor features. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 77-80	3.6	28
208	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. <i>Human Genetics</i> , 2008 , 124, 95-9	6.3	28
207	Utility of the global CDR plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, 106-117	1.2	27
206	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. <i>Acta Neuropathologica</i> , 2018 , 136, 389-404	14.3	27
205	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 503-7	3.6	27
204	Therapy and management of frontal lobe dementia patients. <i>Neurology</i> , 2001 , 56, S41-5	6.5	27
203	Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study. <i>Dysphagia</i> , 1999 , 14, 165-8	3.7	27
202	Progressive Supranuclear Palsy and Corticobasal Degeneration	135-155	27
201	Rate of decline in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014 , 29, 463-8	7	26

200	Biology and neuropathology of dementia in syphilis and Lyme disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 825-44	3	26
199	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , 2000 , 15, 446-458	7	26
198	Clinical and genetic aspects of progressive supranuclear palsy. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998 , 11, 107-14	3.8	26
197	Caregiving in progressive supranuclear palsy. <i>Neurology</i> , 1998 , 51, 1303-9	6.5	26
196	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. <i>Alzheimer's and Dementia</i> , 2020 , 16, 118-130	1.2	25
195	Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. <i>Neurology</i> , 1991 , 41, 1257-62	6.5	25
194	Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. <i>Human Molecular Genetics</i> , 2018 , 27, 3951-3963	5.6	24
193	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 279-289	6.5	24
192	Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013 , 35, 926-33	2.1	23
191	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
190	Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?. <i>Neurology</i> , 1996 , 47, 1324-6	6.5	22
189	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018 , 33, 1750-1759	7	22
188	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0201964	3.7	21
187	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019 , 34, 430-435	7	21
186	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1218-1228	1.2	20
185	Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 197	5.3	19
184	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
183	Unraveling progressive supranuclear palsy: from the bedside back to the bench. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S341-6	3.6	18

182	Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?. <i>European Journal of Neurology</i> , 2003 , 10, 103-6	6	18
181	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020 , 16, 11-21	1.2	18
180	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020 , 16, 37-48	1.2	18
179	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18
178	A disposable electrochemical biosensor for L-DOPA determination in undiluted human serum. <i>Electrochemistry Communications</i> , 2014 , 48, 28-31	5.1	17
177	Current and future treatments in progressive supranuclear palsy. <i>Current Treatment Options in Neurology</i> , 2006 , 8, 211-23	4.4	17
176	Progressive supranuclear palsy: Advances in diagnosis and management. <i>Parkinsonism and Related Disorders</i> , 2020 , 73, 105-116	3.6	17
175	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020 , 16, 49-59	1.2	17
174	Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 54-60	3.6	17
173	The clinical and pathologic hallmarks of progressive supranuclear palsy. <i>Current Opinion in Neurology</i> , 1997 , 10, 346-50	7.1	16
172	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. <i>Neurocase</i> , 2005 , 11, 250-62	0.8	16
171	Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. <i>Neurology</i> , 2018 , 91, 797-799	6.5	16
170	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1451-1457	50.5	16
169	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 926-939	27.4	16
168	Does reversed laterality really exist in dextrals? A case study. <i>Neuropsychologia</i> , 1986 , 24, 241-54	3.2	15
167	Behçet's syndrome masquerading as tumor. <i>Neuroradiology</i> , 1987 , 29, 103	3.2	15
166	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020 , 35, 650-661	7	14
165	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 349-361	5.9	14

164	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016 , 25, 81-8	3.7	14
163	Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans. <i>Frontiers in Neurology</i> , 2018 , 9, 474	4.1	14
162	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 127-134	2.2	14
161	Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson's Disease. <i>Timing and Time Perception</i> , 2014 , 2, 145-168	0.7	14
160	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012 , 27, 1308-11	7	14
159	Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials. <i>Neurology</i> , 2020 , 94, e2384-e2395	6.5	14
158	Cognition in movement disorders: where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014 , 29, 704-11	7	13
157	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 751-3	5.5	13
156	Clinical symptoms in Alzheimer's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 207-16	3	13
155	Parkinsonian features: when are they Parkinson disease?. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1654-5	27.4	13
154	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. <i>Neurology</i> , 2020 , 94, e774-e784	6.5	13
153	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
152	The virtual reality of Parkinson's disease freezing of gait: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 26-33	3.6	13
151	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 971-81	5.3	12
150	Functional impairment in progressive supranuclear palsy. <i>Neurology</i> , 2013 , 80, 380-4	6.5	12
149	The Epidemiology of vascular dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 639-58	3	12
148	Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991 , 54, 832-5	5.5	12
147	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021 , 96, e2296-e2312	6.5	12

146	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. <i>Angewandte Chemie - International Edition</i> , 2021 , 60, 19074-19078	16.4	12
145	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018 , 33, 468-472	7	11
144	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 87-93	3.6	11
143	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 34-39	3.6	11
142	Dysfunction of Ib (autogenic) spinal inhibition in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 1998 , 13, 668-72	7	11
141	Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration		11
140	Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. <i>Cogent Psychology</i> , 2016 , 3, 1131476	1	11
139	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 520-527	7	10
138	Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019 , 47, 187-197	2.6	10
137	Impairment of eyeblink classical conditioning in progressive supranuclear palsy. <i>Movement Disorders</i> , 2001 , 16, 240-51	7	10
136	What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?. <i>Brain</i> , 1996 , 119 (Pt 3), 831-9	11.2	10
135	Apolipoprotein E4 (epsilon) allele does not affect the onset or symptom severity in progressive supranuclear palsy. <i>Archives of Neurology</i> , 1998 , 55, 752-4		10
134	[O21701]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER'S DISEASE 2017 , 13, P599-P600		9
133	Swallowing disturbances in the corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1342-8	3.6	9
132	Neuropathology of Pick body disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 415-30	3	9
131	Clinical aspects and biology of normal pressure hydrocephalus. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 887-902	3	9
130	Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 393-414	3	9
129	Ideomotor apraxia in progressive supranuclear palsy: a case study. <i>Movement Disorders</i> , 1999 , 14, 162-6	7	9

128	Does the Geriatric Depression Scale measure depression in Parkinson's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1662-1670	3.9	9
127	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017 , 35, 75-81	3.6	8
126	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1655-1662	7	8
125	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. <i>Neurodegenerative Diseases</i> , 2018 , 18, 173-190	2.3	8
124	Frontrunner in Translation: Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2019 , 10, 1125	4.1	8
123	A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. <i>Neurology</i> , 1999 , 52, 404-6	6.5	8
122	Examining the motor phenotype of patients with both essential tremor and Parkinson's disease. <i>Tremor and Other Hyperkinetic Movements</i> , 2012 , 2,	2	8
121	Abnormal distraction and load-specific connectivity during working memory in cognitively normal Parkinson's disease. <i>Human Brain Mapping</i> , 2020 , 41, 1195-1211	5.9	8
120	Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. <i>Frontiers in Neurology</i> , 2020 , 11, 897	4.1	8
119	A Microstirring Pill Enhances Bioavailability of Orally Administered Drugs. <i>Advanced Science</i> , 2021 , 8, 2100389	13.6	8
118	Relationship between uric acid levels and progressive supranuclear palsy. <i>Movement Disorders</i> , 2016 , 31, 663-7	7	8
117	Factor Analysis of the Apathy Scale in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 379-386	2.2	7
116	Hypertension and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 166-170	3.6	7
115	Brain-lung-thyroid disease: clinical features of a kindred with a novel thyroid transcription factor 1 mutation. <i>Journal of Child Neurology</i> , 2012 , 27, 68-73	2.5	7
114	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. <i>Movement Disorders</i> , 2008 , 23, 1596-601	7	7
113	An open letter to the Committee on The Nobel Prize in Medicine. <i>Parkinsonism and Related Disorders</i> , 2001 , 7, 149-55	3.6	7
112	What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?. <i>Neurology</i> , 1995 , 45, 387-9	6.5	7
111	Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021 , 11,	2.3	7

110	Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 717-723	2.2	6
109	Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 253-265	1.1	6
108	Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 387-394	6	6
107	H1/H1 genotype influences symptom severity in corticobasal syndrome. <i>Movement Disorders</i> , 2010 , 25, 760-3	7	6
106	Methodological and research issues in the evaluation of biological diagnostic markers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998 , 19, 121-3	5.6	6
105	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 671-86	3	6
104	The neuropathology of vascular and mixed dementia and vascular cognitive impairment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 687-703	3	6
103	Current and future therapeutic approaches in progressive supranuclear palsy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 493-508	3	6
102	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. <i>Frontiers in Neurology</i> , 2021 , 12, 648532	4.1	6
101	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
100	Therapeutic options for Progressive Supranuclear Palsy including investigational drugs. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 575-587	1.1	5
99	Genetic influences on cognition in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017 , 32, 1764-1771		5
98	End of life planning in parkinsonian diseases. <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 73-78	3.6	5
97	The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners. <i>Quality of Life Research</i> , 2019 , 28, 2705-2716	3.7	5
96	Cognitive functioning in individuals with Parkinson's disease and traumatic brain injury: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2016 , 30, 58-61	3.6	5
95	Correcting for demographic variables on the modified telephone interview for cognitive status. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 1438-43	6.5	5
94	Is EEG useful in the differential diagnosis of parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1998 , 4, 79-80	3.6	5
93	Update of atypical Parkinsonian disorders. <i>Current Opinion in Neurology</i> , 2007 , 20, 434-7	7.1	5

92	Progressive Supranuclear Palsy 2005 , 287-308		5
91	What is an Atypical Parkinsonian Disorder? 2005 , 1-9		5
90	CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. <i>Acta Neurologica Scandinavica</i> , 1992 , 86, 204-6	3.8	5
89	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 797-808	5.2	5
88	Anti-inflammatory drug use and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018 , 48, 89-92	3.6	5
87	Wearable electrochemical microneedle sensing platform for real-time continuous interstitial fluid monitoring of apomorphine: Toward Parkinson management. <i>Sensors and Actuators B: Chemical</i> , 2022 , 354, 131234	8.5	4
86	The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World. <i>Lecture Notes in Computer Science</i> , 2015 , 412-422	0.9	4
85	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 121-126	3.6	4
84	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 56-60	3.6	4
83	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 138-145	3.6	4
82	Progress in the treatment of Parkinson-Plus syndromes. <i>Parkinsonism and Related Disorders</i> , 2019 , 59, 101-110	3.6	4
81	Brain volumetric deficits in MAPT mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 95-110	5.3	4
80	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. <i>Angewandte Chemie</i> , 2021 , 133, 19222-19226	3.6	4
79	Levodopa-Responsive Parkinsonism Associated with Giant Virchow-Robin Spaces: A Case Report. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 619-622	2.2	3
78	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. <i>Neurology</i> , 2020 , 95, e35-e45	6.5	3
77	Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of multiple system atrophy. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 693-8	5.3	3
76	The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 377-383	5.3	3
75	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. <i>BMC Medical Genetics</i> , 2012 , 13, 16	2.1	3

74	Clinical and therapeutic aspects of dementia in syphilis and Lyme disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 819-23</i>	3	3
73	Quality of life in dementias. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 97-100</i>	3	3
72	PROGRESSIVE SUPRANUCLEAR PALSY. <i>Neurologist, 1998, 4, 13-20</i>	1.6	3
71	Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. <i>Brain, 2020, 143, 2868-2871</i>	11.2	3
70	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders, 2020, 80, 127-132</i>	3.6	3
69	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. <i>Frontiers in Neurology, 2021, 12, 571800</i>	4.1	3
68	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. <i>Cortex, 2021, 139, 99-115</i>	3.8	3
67	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. <i>Movement Disorders Clinical Practice, 2016, 3, 65-67</i>	2.2	3
66	Sex differences for phenotype in pathologically defined dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 745-750</i>	5.5	3
65	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders, 2021, 83, 115-122</i>	3.6	3
64	Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease. <i>Frontiers in Aging Neuroscience, 2018, 10, 331</i>	5.3	3
63	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy, 2019, 11, 23</i>	9	2
62	Pathology-Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. <i>Movement Disorders Clinical Practice, 2020, 7, 267-272</i>	2.2	2
61	Progressive Supranuclear Palsy and Statin Use. <i>Movement Disorders, 2020, 35, 1253-1257</i>	7	2
60	Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines. <i>Movement Disorders, 2012, 27, 1707-1707</i>	7	2
59	Primary health care providers' knowledge gaps on Parkinson's disease. <i>Educational Gerontology, 2013, 39, 856-862</i>	1.2	2
58	Neuropsychiatric and cognitive disorders in other parkinsonian disorders261-274		2
57	Neuropathology and genetics of corticobasal degeneration. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 523-32</i>	3	2

56	Cerebellar cognition. <i>Neurology</i> , 1993 , 43, 2153-2153	6.5	2
55	Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2021 , 28, 812-828	2.1	2
54	Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 585-596	3.8	2
53	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021 , 7, 16	9.7	2
52	TRANSCENDS: A Career Development Program for Underrepresented in Medicine Scholars in Academic Neurology. <i>Neurology</i> , 2021 ,	6.5	2
51	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2
50	Hispanic Perspectives on Parkinson's Disease Care and Research Participation. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 809-819	4.3	2
49	Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1281, 151-176	3.6	2
48	Medication Management Performance in Parkinson's Disease: Examination of Process Errors. <i>Archives of Clinical Neuropsychology</i> , 2021 , 36, 1307-1315	2.7	2
47	Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1539-1548	4.3	2
46	Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 30	9.7	2
45	Treatment of Progressive Supranuclear Palsy. <i>Current Clinical Neurology</i> , 2019 , 137-140	0.1	1
44	Occupation and Parkinson disease in the Women's Health Initiative Observational Study. <i>American Journal of Industrial Medicine</i> , 2019 , 62, 766-776	2.7	1
43	Measuring quality of life in progressive supranuclear palsy52-59		1
42	Perspectives of Alzheimer's disease treatments. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 273-90	3	1
41	History of dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 3-13	3	1
40	Diagnostic issues in non-AD dementias. <i>Clinical Neuroscience Research</i> , 2004 , 3, 363-374		1
39	Atypical parkinsonism in the French West Indies. <i>Lancet, The</i> , 1999 , 354, 1472-3	40	1

38	Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease. <i>Developmental Neuropsychology</i> , 1988 , 4, 295-302	1.8	1
37	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , 2021 , 12, 805135	4.1	1
36	Progressive Supranuclear Palsy and Corticobasal Degeneration 2005 , 505-514		1
35	Informant-Reported Cognitive Decline is Associated with Objective Cognitive Performance in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 439-449	3.1	1
34	Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson's Disease: A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022 , 35, 89-101	3.8	1
33	Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 961-964	2.2	1
32	Association of Stress-Health Factors among Parkinson's Disease Patient/Caregiving-Partner Dyads. <i>Archives of Clinical Neuropsychology</i> , 2021 ,	2.7	1
31	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021 , 12, 664746	4.6	1
30	Environmental Risk Factors for Progressive Supranuclear Palsy. <i>Journal of Movement Disorders</i> , 2021 , 14, 103-113	2.9	1
29	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. <i>Frontiers in Neurology</i> , 2021 , 12, 694872	4.1	1
28	Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 92-99	2.2	1
27	Proposed research criteria for prodromal behavioural variant frontotemporal dementia.. <i>Brain</i> , 2022 ,	11.2	1
26	Semantic Recollection in Parkinson's Disease: Functional Reconfiguration and MAPT Variants. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 727057	5.3	1
25	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 501-502	7	0
24	The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 463-5	3.6	0
23	Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report. <i>Clinical Autonomic Research</i> , 2020 , 30, 575-577	4.3	0
22	Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [1]FP-CIT SPECT/CT Brain Imaging. <i>Tomography</i> , 2021 , 7, 95-106	3.1	0
21	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021 , 97, e814-e824	6.5	0

20	Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 99-100	2.2	0
19	Internetwork Connectivity Predicts Cognitive Decline in Parkinson's and Is Altered by Genetic Variants.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 853029	5.3	0
18	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
17	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.. <i>Cell Reports Medicine</i> , 2022 , 3, 100607	1.8	0
16	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042846	1.2	
15	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045482	1.2	
14	Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD). <i>Alzheimer's and Dementia</i> , 2020 , 16, e046247	1.2	
13	Woman with gait impairment and difficulty reading229-237		
12	Reply: Corticobasal syndrome with Alzheimer's disease pathology. <i>Movement Disorders</i> , 2009 , 24, 153-153		
11	Limb shaking in multiple system atrophy. <i>European Journal of Neurology</i> , 1998 , 5, 113-115	6	
10	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 303-6	3	
9	Progressive supranuclear palsy and corticobasal degeneration: similarities and differences. <i>Future Neurology</i> , 2008 , 3, 299-307	1.5	
8	Neurobiology of Progressive Supranuclear Palsy 2007 , 105-110		
7	ATYPICAL PARKINSONIAN DISORDERS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2004 , 10, 42-64	3	
6	Clinicopathologic case report. Dementia with Lewy bodies (DLB). <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999 , 11, 107-12	2.7	
5	Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees. <i>Lecture Notes in Computer Science</i> , 2004 , 1018-1024	0.9	
4	Is it PD, PSP, CBD, DLB, or MSA? 2008 , 219-222		
3	Parkinson's Disease: An Overview of Pathogenesis 2009 , 159-178		

2 P1-433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC MAPT MUTATION CARRIERS **2018**, 14, P475-P476

1 Reply to: "Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?". *Movement Disorders*, **2021**, 36, 1999-2000

7